A Pharmacogenomic Study of Candesartan in Heart Failure
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the impact of genetic variations on the response to
candesartan in patients with heart failure who are already treated with an ACE inhibitor.